A detailed history of Vanguard Group Inc transactions in Cerus Corp stock. As of the latest transaction made, Vanguard Group Inc holds 9,983,963 shares of CERS stock, worth $17.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,983,963
Previous 9,870,671 1.15%
Holding current value
$17.9 Million
Previous $21.3 Million 11.5%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$1.66 - $2.42 $188,064 - $274,166
113,292 Added 1.15%
9,983,963 $18.9 Million
Q4 2023

Feb 14, 2024

BUY
$1.25 - $2.35 $151,783 - $285,353
121,427 Added 1.25%
9,870,671 $21.3 Million
Q3 2023

Nov 14, 2023

SELL
$1.5 - $3.07 $514,578 - $1.05 Million
-343,052 Reduced 3.4%
9,749,244 $15.8 Million
Q2 2023

Aug 14, 2023

SELL
$1.79 - $2.9 $806,548 - $1.31 Million
-450,586 Reduced 4.27%
10,092,296 $24.8 Million
Q1 2023

May 15, 2023

SELL
$2.65 - $3.81 $947,481 - $1.36 Million
-357,540 Reduced 3.28%
10,542,882 $31.3 Million
Q4 2022

Feb 10, 2023

BUY
$3.38 - $4.22 $1.51 Million - $1.89 Million
447,371 Added 4.28%
10,900,422 $39.8 Million
Q3 2022

Nov 14, 2022

BUY
$3.43 - $5.83 $4.19 Million - $7.13 Million
1,222,273 Added 13.24%
10,453,051 $37.6 Million
Q2 2022

Aug 12, 2022

BUY
$4.41 - $5.69 $830,698 - $1.07 Million
188,367 Added 2.08%
9,230,778 $48.8 Million
Q1 2022

May 13, 2022

BUY
$4.81 - $6.99 $1.06 Million - $1.53 Million
219,535 Added 2.49%
9,042,411 $49.6 Million
Q4 2021

Feb 14, 2022

SELL
$5.97 - $7.93 $34,363 - $45,645
-5,756 Reduced 0.07%
8,822,876 $60.1 Million
Q3 2021

Nov 12, 2021

SELL
$4.79 - $6.68 $25,272 - $35,243
-5,276 Reduced 0.06%
8,828,632 $53.8 Million
Q2 2021

Aug 13, 2021

BUY
$5.35 - $6.35 $47.3 Million - $56.1 Million
8,833,908 New
8,833,908 $52.2 Million

Others Institutions Holding CERS

About CERUS CORP


  • Ticker CERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 177,090,000
  • Market Cap $317M
  • Description
  • Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...
More about CERS
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.